Sign in
Taking peoplePhase 1/2

Eltrombopag added to prednisolone for newly diagnosed immune thrombocytopenia

Tests eltrombopag as first treatment in adults newly diagnosed with immune thrombocytopenia.

Key facts

Who runs it
Renata PLC
Where
Bangladesh1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
Role of Eltrombopag as First Line Therapy in Primary Immune Thrombocytopenia.
Status
Recruiting
Phase
Phase 1/2
People taking part
100 people, planned
Started
7 Feb 2025
Planned end
31 Dec 2025
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Eltrombopag 25 MG
  • Prednisolone
Record updated
18 February 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with newly diagnosed primary immune thrombocytopenia (ITP), a condition where the immune system destroys platelets. It compares eltrombopag plus prednisolone with placebo plus prednisolone.

Age
18 to 70 years
Sex
All sexes
Disease stage
Newly diagnosed ITP. Persistent or chronic ITP cannot join.
Biomarker or test result
Platelet count ≤ 30x109/L

Main reasons for not taking part

  • Pregnant women
  • ITP caused by another disease, such as SLE, anti-phospholipid syndrome, Evans syndrome, HCV or H Pylori
  • Recent vaccination, recent viral infection or fever
  • Known chronic kidney failure or liver disease
  • Grade 3 or 4 bleeding when first seen

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Patients with newly diagnosed ITP
  • Platelet Count ≤ 30x109/L
  • Age between 18 to 70 years

Who cannot take part

  • Secondary ITP- ITP due to SLE, Anti-phospholipid syndrome, Evans syndrome, HCV or H Pylori associated ITP
  • History of vaccination, recent viral infection, fever
  • Evan's Syndrome
  • Known case of chronic renal failure or liver diseases
  • Grade 3 or 4 bleeding at presentation
  • Persistent or chronic ITP
  • Pregnant women

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 70 years old?

This trial is currently available in Bangladesh.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This will be a double-blind, placebo-control, randomized clinical trial conducted in the Department of Hematology, DMCH for one year. This study will help to establish the role of eltrombopag as a first-line therapy in newly diagnosed ITP. Newly diagnosed ITP patients will be selected after meeting inclusion and exclusion criteria, they will be thoroughly informed about the study, used drugs, randomization, risks, benefits, and follow-up. If they agree to participate, their consent will be taken and they will be enrolled in the study. A detailed history and clinical exam will be done. Primary investigation will be - CBC PBF, RBS, ANA, TSH, Anti H. pyloriIgG, Anti-HCV, APTT, and BMS (if indicated). The main outcome variable will be platelet count and number of spontaneous bleeding. Total sample size would be 100 (50 in each group). Enrolled patients would be divided into two groups (1:1) by block randomization. One group will get Eltrombopag\& Prednisolone and other group will get Eltrombopag\& Placebo. Researchers or any one related to the study in DMCH, patients \& their attendants, no one will know which patient will get placebo or eltrombopag. Only a respectable third party will know the information. A patient would be followed up on 1st, 2nd and 4th week of starting therapy. Patients would be evaluated in every follow up by history, physical examination and investigation. History of any spontaneous bleeding event, any discomfort or new symptoms science last follow up will be noted. General examination will be performed in every follow-up. CBC, RBS, ALT, AST, creatinine will be done in every follow-up. Data will be collected on a pre-designed case record form and will be collected through face-to-face interviews, physical examination, and laboratory reports. After data collection data will be edited, cleaned, and prepared for analysis at the end of the study. The statistical analysis will be conducted using SPSS version 25 statistical software. The results of the study will be published in national and international journals.

The 2 groups in the trial

  • Eltrombopag ArmTreatment being tested

    Eltrombopag + Prednsolone

    Treatment: Eltrombopag 25 MG and Prednisolone

  • Prednisolone alone armPlacebo, for comparison

    Placebo + Prednisolone

    Treatment: Prednisolone

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Efficacy of Eltrombopag & Prednisolone Versus Prednisolone Monotherapy in Newly Diagnosed Immune Thrombocytopenia- A Randomized Control Trial
Plain-language title
Eltrombopag added to prednisolone for newly diagnosed immune thrombocytopeniaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Criteria questions
Built from NCT06531018, who can take part
Record updated
18 February 2025